AI Article Synopsis

  • The study investigates if core needle biopsy offers enough tissue for accurate evaluation of PD-L1 in non-small cell lung carcinoma (NSCLC).
  • Despite the heterogeneous expression of PD-L1, results from 51 core biopsies showed strong agreement with subsequent surgical resection samples, with 92.2% concordance.
  • The findings indicate that core biopsies are likely sufficient for assessing PD-L1 levels in NSCLC, but resection specimens may still be useful for checking low-level staining.

Article Abstract

The heterogeneity of programmed death ligand 1 (PD-L1) expression in non-small cell lung carcinomas (NSCLCs) is well studied; however, the method of tissue sampling needed to obtain adequate diagnostic material has not been established. This study aimed to determine whether core needle biopsy provides sufficient tissue for accurate PD-L1 evaluation despite tumor heterogeneity. A retrospective analysis comparing tumoral expression of PD-L1 in 51 lung core biopsies to subsequent resection specimens was performed. Scoring of membranous staining was categorized as 0%, 1% to 49%, and ≥50% of tumor cells. Staining ≥50% tumoral PD-L1 expression was detected in 8/51 (15.7%) of core biopsies and 8/51 (15.7%) of resection specimens. Core biopsy and resection results were concordant in 92.2% of cases (κ, 0.70; 95% confidence interval, 0.43-0.98). Therefore, despite tumor heterogeneity, detection of tumoral PD-L1 expression in NSCLC appears to be largely concordant between core biopsies and resection specimens, with the caveat that it may be helpful to reassess resection specimens for low-level staining. These findings suggest that core biopsy may be adequate for determining PD-L1 expression in NSCLC.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001085DOI Listing

Publication Analysis

Top Keywords

pd-l1 expression
20
resection specimens
20
core biopsy
12
core biopsies
12
biopsy resection
8
non-small cell
8
cell lung
8
despite tumor
8
tumor heterogeneity
8
tumoral pd-l1
8

Similar Publications

This study investigates the prognostic value of serum biomarkers PD-L1 and IGFBP-2 in patients with esophageal carcinoma. It finds a significant positive correlation between these biomarkers and established tumor markers CEA and CYFRA21-1. The 3-year survival rate for the patient cohort was 45.

View Article and Find Full Text PDF

Background: Immunotherapy is increasingly significant in treating metastatic gastric cancer. This prospective phase 2 study investigates the efficacy and safety of combining nivolumab with chemotherapy in patients with metastatic gastric cancer co-expressing FGFR2 and PD-L1.

Methods: Eligible patients were aged 18 years or older, with previously untreated HER-2 negative, PD-L1 positive, and FGFR2 positive metastatic gastric adenocarcinoma.

View Article and Find Full Text PDF

Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model.

J Control Release

January 2025

Precision Medicine in Oncology (PrMiO), and Nanomedicine Innovation Center Erasmus (NICE), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address:

The recent approval of pembrolizumab in recurrent or metastatic cervical cancer warrants further investigations into the usefulness of immunotherapies for more durable and less radical interventions. In this study, the targeting potential of anti-PD-L1-functionalized immunoliposomes was tested in a 3D in vitro cervical cancer-on-a-chip model. Immunolipsomes were synthesized and decorated externally with monovalent anti-PD-L1 Fab' fragments of commercially available atezolizumab.

View Article and Find Full Text PDF

Aim: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the phase III randomized study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9).

Methods: Cemiplimab (n = 304) or chemotherapy (n = 304) were administered every 3 weeks.

View Article and Find Full Text PDF

STAT3-related lncRNAs in colorectal cancer progression; Special focus on immune cell's evasion.

Pathol Res Pract

January 2025

Medical laboratory technique college, the Islamic University, Najaf, Iraq; Medical laboratory technique college, the Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.

Colorectal cancer (CRC) is globally ranked as the third leading cause of cancer-related deaths in both men and women. There is an urgent need for novel biomarkers to facilitate early diagnosis and enhance patient care, thereby improving treatment response and reducing mortality rates. Signal transducer and activator of transcription 3 (STAT3) is essential for controlling the anti-tumor immune response since it is a hub for several oncogenic signaling pathways.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!